Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.
Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Caribou Biosciences (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in upcoming investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, is scheduled to present at two events in June:
1. Jefferies Healthcare Conference in New York, NY on June 7, 2023, at 3:00 pm EDT
2. Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on June 13, 2023, at 3:20 pm PDT
Both presentations will be available via webcast. Interested parties can access the webcasts through the Events page on Caribou's website. The recordings will remain accessible for 30 days after each event.
Caribou Biosciences (Nasdaq: CRBU) reported Q1 2023 financial results and provided a business update. Key highlights include:
1. CB-010: Dose expansion in ANTLER Phase 1 trial for second-line LBCL patients; dose escalation data expected in H2 2023.
2. CB-011: CaMMouflage Phase 1 trial enrolling r/r MM patients; received Fast Track designation.
3. CB-012: IND application for r/r AML planned for H2 2023.
4. Financial position: $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023; runway into 2025.
5. Q1 2023 results: Revenue $3.5 million, R&D expenses $25.7 million, G&A expenses $8.9 million, net loss $28.0 million.